Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 23, 2007
- 7 Drugs Transiently Excluded from DPC
July 23, 2007
- Excessive Thoroughness Should Be Eliminated in Source Data Verification: Seminar
July 23, 2007
- Hospital Stay Shortens but Readmission Rate Rises under the Current DPC System
July 23, 2007
- Korosho Calls on Pharmacists to Actively Participate in Anticancer Chemotherapy
July 23, 2007
- MCH to Search Cerebral Infarction Biomarkers with Kyushu Univ.
July 23, 2007
- Evista to Reach \20 Bil. Sales Goal Ahead of Schedule
July 23, 2007
- Comtan Stabilizes Levodopa Concentrations: Novartis Seminar
July 23, 2007
- MTPC Aims to Successively Launch Global Products, Stably Supply High-Quality Essential Drugs: Mr Hayama
July 23, 2007
- 10 APIs Recommended for Approval by CDFS's Dept. on Drugs
July 16, 2007
- AntiCancer Inc. Opens Bioimaging Research Lab in Osaka
July 16, 2007
- BUSINESS NEWS IN BRIEF
July 16, 2007
- REGULATORY NEWS IN BRIEF
July 16, 2007
- Banyu's Preminent Shows Highest Awareness Rate: Survey
July 16, 2007
- Ryukaikon to Focus on Business Between Makers and Wholesalers
July 16, 2007
- Eyeforpharma Sales Force Effectiveness Japan 2007
July 16, 2007
- Diovan Ranked No. 1 for 2 Months in a Row in Rep Track Survey
July 16, 2007
- Blopress Ranks No. One 3 Times in 3 Years: Top-100 Drug Ranking
July 16, 2007
- Nexavar to Become Standard Therapy for Hepatocellular Carcinoma
July 16, 2007
- Nippon Kayaku Aims at Sales of \10 Billion with Generics
July 16, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…